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Hypothermia protects human neurons
Abstract

Background and Aims: Hypothermia provides neuroprotection after cardiac arrest, hypoxic-ischemic
encephalopathy, and in animal models of ischemic stroke. However, as drug development for stroke has been
beset by translational failure, we sought additional evidence that hypothermia protects human neurons against
ischemic injury.
Methods: Human embryonic stem cells were cultured and differentiated to provide a source of neurons
expressing β III tubulin, microtubule-associated protein 2, and the Neuronal Nuclei antigen. Oxygen
deprivation, oxygen-glucose deprivation, and H2O2 -induced oxidative stress were used to induce relevant
injury.
Results: Hypothermia to 33°C protected these human neurons against H2O2 -induced oxidative stress
reducing lactate dehydrogenase release and Terminal deoxynucleotidyl transferase dUTP nick end labelingstaining by 53% (P≤0·0001; 95% confidence interval 34·8-71·04) and 42% (P≤0·0001; 95% confidence
interval 27·5-56·6), respectively, after 24 h in culture. Hypothermia provided similar protection against
oxygen-glucose deprivation (42%, P≤0·001, 95% confidence interval 18·3-71·3 and 26%, P≤0·001; 95%
confidence interval 12·4-52·2, respectively) but provided no protection against oxygen deprivation alone.
Protection (21%) persisted against H2O2 -induced oxidative stress even when hypothermia was initiated sixhours after onset of injury (P≤0·05; 95% confidence interval 0·57-43·1).
Conclusion: We conclude that hypothermia protects stem cell-derived human neurons against insults relevant
to stroke over a clinically relevant time frame. Protection against H2O2 -induced injury and combined oxygen
and glucose deprivation but not against oxygen deprivation alone suggests an interaction in which protection
benefits from reduction in available glucose under some but not all circumstances.
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Hypothermia protects human neurons
Ana Antonic1,2, Mirella Dottori3, Jessie Leung3, Kate Sidon1,2, Peter E. Batchelor2,
William Wilson5, Malcolm R. Macleod4, and David W. Howells1,2*
Background and Aims Hypothermia provides neuroprotection
after cardiac arrest, hypoxic-ischemic encephalopathy, and in
animal models of ischemic stroke. However, as drug development for stroke has been beset by translational failure, we
sought additional evidence that hypothermia protects human
neurons against ischemic injury.
Methods Human embryonic stem cells were cultured and differentiated to provide a source of neurons expressing β III
tubulin, microtubule-associated protein 2, and the Neuronal
Nuclei antigen. Oxygen deprivation, oxygen-glucose deprivation, and H2O2-induced oxidative stress were used to induce
relevant injury.
Results Hypothermia to 33°C protected these human neurons
against H2O2-induced oxidative stress reducing lactate dehydrogenase release and Terminal deoxynucleotidyl transferase
dUTP nick end labeling-staining by 53% (P ≤ 0·0001; 95% confidence interval 34·8–71·04) and 42% (P ≤ 0·0001; 95% confidence
interval 27·5–56·6), respectively, after 24 h in culture. Hypothermia provided similar protection against oxygen-glucose deprivation (42%, P ≤ 0·001, 95% confidence interval 18·3–71·3 and
26%, P ≤ 0·001; 95% confidence interval 12·4–52·2, respectively) but provided no protection against oxygen deprivation
alone. Protection (21%) persisted against H2O2-induced oxidative stress even when hypothermia was initiated six-hours after
onset of injury (P ≤ 0·05; 95% confidence interval 0·57–43·1).
Conclusion We conclude that hypothermia protects stem cellderived human neurons against insults relevant to stroke over
a clinically relevant time frame. Protection against H2O2induced injury and combined oxygen and glucose deprivation
but not against oxygen deprivation alone suggests an interaction in which protection benefits from reduction in available
glucose under some but not all circumstances.
Key words: brain, hypothermia, ischemic stroke, neuroprotection, stem
cells, treatment

Introduction
Obstruction of an artery supplying the brain initiates a cascade of
events leading ultimately to necrotic and apoptotic cell death.
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With the most extreme perfusion deficits, survival is unlikely and
cell death is rapid. However, in areas adjacent to the ischemic core
(the ischemic penumbra), residual blood flow can preserve tissue
vitality for a limited time until the obstruction resolves spontaneously or is removed by thrombolysis (1,2). After these acute
events delayed neuronal death may progress for up to three-days
(3). Both these phenomena (the penumbra during ischemia and
delayed neural injury after ischemia) provide targets for treatment and in animal models of ischemic stroke over 500 ‘neuroprotective’ treatment strategies reported improved outcome.
However, none have proved robustly effective in randomized controlled clinical trials (4). Importantly with the exception of therapeutic hypothermia (5), clinical trials of neuroprotection for
stroke have largely been abandoned (http://www.clinicaltrials
.gov).
The reasons for this translational failure have been hotly
debated. Contamination of the preclinical data set by falsely positive results influenced by bias and lack of statistical power offer
some explanation (6–8). The molecular targets of therapy may be
present in rodents but not in man (9), either because of differences in genetic background (10) or because evolution of the
ischemic cascade might proceed at a different pace in different
species (11–13). Additionally, laboratory and clinical thrombolysis experiments show similar, and unfortunately short, windows
of opportunity (2,14), which are frequently unachievable in most
trials of neuroprotection (15,16). Targeting single components of
the ischemic cascade might also limit our chances of success
(17,18), but combinatorial pharmacotherapy therapy brings its
own challenges (19).
The preclinical data set for therapeutic hypothermia is large
(3353 animals) and demonstrates substantial and consistent efficacy, with only modest effects of publication bias and failure to
randomize or blind (20). Hypothermia influences multiple
molecular targets (21,22) and provides benefit over a wide range
of times to treatment in animals (20). Clinically, evidence of a
relationship between body temperature and outcome after
human stroke (23–25), together with the proven neuroprotective
benefit of hypothermia in adults with global ischemia after
cardiac arrest (26,27) and neonates with hypoxic-ischemic
encephalopathy (28,29), suggest that the targets that provide
benefit in animal models of stroke will also be present in human
stroke. However, the absence of clear therapeutic benefit in traumatic brain injury (30), which accrues damage similarly to stroke
(31), suggests caution should be taken. A Cochrane systematic
review of stroke patients treated with physical cooling devices
suggests there may be a trend toward improvement. However, in
most cases, treatment was initiated (8–12 h) when penumbral
tissue, the main putative target, may no longer be present. Overall,
the analysis supports the view that we still have insufficient data
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(32) with trials too small to allow firm conclusions to be made
about the efficacy of hypothermia in stroke patients (33–35).
In this report, we show that hypothermia (33°C) protects
human stem-cell derived neurons from oxidative stress induced
by hydrogen peroxide and from oxygen-glucose deprivation but
not hypoxia alone. Importantly, protection against oxidative
stress is observed at later times (six-hours) than obtained under
oxygen-glucose deprivation. The results were replicated in three
independent series of experiments employing randomization and
blinding of operator-dependent, outcome analyses.

Methods
Human embryonic stem cell (hESC) Culture
Experiments with these cells were carried out in accordance with
the guidelines and regulations of the National Health and Medical
Research Council and with the approval of the Austin Health
Human Research Ethics Committee (Approval number H2008/
03194) and University of Melbourne Human Research Ethics
Committee (Approval number 0605017).
H9 (WA-09, WiCell, Madison, Wisconsin, USA), human
embryonic stem cells (hESC), were cultured on mitomycinC treated mouse embryonic fibroblasts (MEFs) in hESC
medium consisting of high-glucose Dulbecco’s modified
Eagle’s minimal essential medium (DMEM) without sodium
pyruvate, supplemented with insulin/transferrin/selenium 1%,
β-mercaptoethanol 0·1 mM, nonessential amino acids (NEAAs)
1%, glutamine 2 mM, penicillin 25 U/ml, streptomycin 25 μg/ml
(all from Invitrogen, Victoria, Australia) and fetal calf serum
(FCS) 20% (HyClone, Australia) or on mitomycin-C treated
human foreskin fibroblasts (HFF; ATCC, CRL-2097) in KSR
media consisting of DMEM/nutrient mixture F-12, supplemented
with β-mercaptoethanol 0·1 mM, NEAAs 1%, glutamine 2 mM,
penicillin 25 U/ml, streptomycin 25 μg/ml, and knockout serum
replacement 20% (all from Invitrogen). All cells were cultured at
37°C in 5% CO2. Colonies were mechanically dissected every
seven-days and transferred to freshly prepared MEFs or HFFs.
Media was changed every second day.
Neuronal differentiation and growth
Neuronal differentiation was achieved using the noggin induction
method described for mouse neurospheres (36) as adapted by
Dottori for human neurospheres (37).The colonies were maintained (37°C, 5% CO2) in hESC medium supplemented with
500 ng/ml of Noggin (6057-NG, R&D systems, Australia) for 14
days with the media and Noggin replaced every second day.
At this point, the colonies were again mechanically dissociated,
but at this time the central (differentiated) part of the colony was
also cut into smaller pieces using a 26-gauge needle. The pieces
were transferred to individual wells in a low adherent 96-well
plate containing Neural Basal Media (NBM) that contains Neurobasal A (10888-022, Invitrogen) supplemented with 2% B27
(17504-044, Invitrogen), 1% Insulin Transferrin Selenium-A
(51500-056, Invitrogen), 1% N2 (17502-048, Invitrogen), 2 mM
glutamine, 0·5% Penicillin-Streptomycin Solution (15070-063,
Invitrogen), 20 ng/ml human recombinant epidermal growth

factor (EGF) (PHG0314, Invitrogen) and 20 ng/ml human
recombinant basic fibroblast growth factor (bFGF) (13256-029,
Invitrogen). Media was changed every two- to three-days to allow
neurosphere formation over two-weeks.
In order to facilitate neuronal differentiation, neurospheres
were again separated into smaller pieces under a dissection microscope with three to four pieces transferred to each well of a
96-well plate [precoated with poly-D-lysine (10 μg/ml) and
mouse laminin (5 μg/ml)]. The cells were then grown for 11 days
(with media changed every two-days) in NBM lacking
growth factors prior to induction of injury and assessment of
hypothermia.
Injury and hypothermia induction
On the day of experiments, the medium was changed to
NBM+N2 containing a B27 preparation lacking the usual antioxidants (10889-038, Invitrogen) (NBM-AO) to eliminate their confounding effects.
Three different injury models were used to assess the effect of
hypothermia on these cells. Oxygen deprivation was induced by
placing the cells into a hypoxic chamber flushed with nitrogen for
20 min and maintained at the appropriate temperature (33°C or
37°C) for four-hours inside a standard 5% CO2 incubator. Culture
supernatant was removed after this four-hour period and stored
at 4°C until analysed for lactate dehydrogenase activity (LDH).
The media was replaced with fresh NBM-AO, and the cells were
incubated for a further 20 h at the appropriate temperature (33°C
or 37°C) before again measuring LDH. For combined oxygen and
glucose deprivation (ODG), 25 mM 2-deoxy-D-glucose was
added to NBM-AO medium and equilibrated for 30 min at room
temperature before the initial media change as described above.
The third injury model used was oxidative stress induced by
adding 50 μM of fresh H2O2 (H1009, Sigma-Aldrich, Australia) to
the NBM-AO for four-hours (33°C or 37°C, 5% CO2) when LDH
was measured, and NBM-AO without H2O2 was returned to the
culture, which was maintained for a further 20 h before again
measuring LDH. To examine whether the effects of injury continued beyond four-hours, the media containing the above stressors was removed and replaced with fresh growth factor negative
NBM before resampling for LDH activity and assessment of
apoptotic cell death by terminal deoxynucleotidyl transferase
dUTP nick end labelling (TUNEL) staining at 24 h.
To evaluate the effects of hypothermia over time from the
induction of injury, incubation at 33°C was started immediately,
or one-, or three-, or six-hours after induction of injury and
maintained until a total of 24 h in each of the models.
LDH, a marker of total cell death and TUNEL staining and a
marker of DNA damage typical of apoptosis, were performed
according to the kit manufacturer’s instructions (1164479001 and
11684795910, respectively, Roche, Australia). For LDH assays,
three control measurements were made in addition to the test
sample measurements. The cell culture medium without cells was
assayed to assess background activity. Uninjured cells were
assayed to detect activity due to basal cell death, and maximum
possible cell death (100%) was detected by measuring LDH activity of lysed cells.
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Fig. 1 β III tubulin positive human neurons after 11 days in culture with
nuclei counterstained with 4’,6-diamidino-2-phenylindole dihydrochloride
(DAPI).

Statistical analysis
Each experiment was repeated three times. To avoid systematic
effects on individual cultures because of the arrangement of wells
in the tissue culture plates, control and injury cultures were distributed across the plates at random. Complete experiments contained within each tissue culture plate were then placed
alternatively at either 37OC or 33OC. To minimize the potential
impact of systematic bias, before counting of TUNEL positive
cells, wells were imaged and the images recoded independently
before quantitation. No additional blinding was performed for
the machine-read LDH assay process. Within experiments, each
comparison was performed at least in triplicate and the mean of
these values taken forward into group comparisons. Two-way
analysis of variance was performed, followed by post hoc Dunnett’s multiple comparison test with significance set at P < 0·05
using spss (Statistics 20, IBM, Armonk, NY, USA). All values are
presented as mean ± standard error of the mean.

Results
The method of stem cell culture and neuronal differentiation
employed in this study gives rise to neurons with a mature projecting phenotype (Fig. 1) that express the markers β III tubulin,
microtubule-associated protein 2 (MAP2), and neural nuclei
(NeuN). β III tubulin positive cells comprise 70·4% ± 1·8 of the
cells present before injury (obtained by calculating the ratio of
4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) and β III
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tubulin cells from 10 fields per well in three independent experiments). Dose response assays were performed to establish injury
assay conditions (hypoxia, hypoxia plus glucose deprivation, and
oxidative stress) that reproducibly induced 30–40% of maximal
signal at four-hours to ensure that values lay within the working
range of the assays used. In control cultures without injury, hypothermia had no effect on the basal level of cell death measured by
LDH release at either 4 or 24 h (Figs 2–5).
H2O2-induced oxidative stress increased LDH-detected cell
death 3·8-fold after four-hours. Removal of the H2O2 by replacing
the culture media at four-hours dramatically slowed but did not
halt the H2O2-induced injury (Fig. 2a,b). Hypothermia to 33°C
reduced H2O2-induced cell death at four-hours by 45%
[P ≤ 0·0001; 95% confidence interval (CI) 27·5–62·6] (after correcting for basal injury in controls) (Fig. 2a). Hypothermia effectively abolished (92% reduction) (P ≤ 0·001; 95% CI 45·3–131·3)
the delayed injury that continued to accrue between removal of
H2O2 at four-hours and completion of the experiment at 24 h
(Fig. 2b). The net effect at 24 h was a reduction of LDH release of
53% (P ≤ 0·0001; 95% CI 34·8–71·04) (Fig. 2c). H2O2-induced
oxidative stress increased TUNEL-detected apoptotic cell death
2·9-fold after 24 h, with 22% of cells present in culture killed by
this mechanism upon introduction of H2O2. Hypothermia prevented 42% (P ≤ 0·0001; 95% CI 27·5–56·6) of this death (after
correcting for basal injury in the control) (Fig. 2d).
Oxygen deprivation alone increased LDH-detected cell death
approximately twofold after four-hours. Restoring the culture to a
normal air/5% CO2 incubator and replacing the culture media at
four-hours again slowed but did not completely halt the oxygen
depletion induced injury (Fig. 3a,b). Hypothermia to 33°C had
no discernible effect on oxygen depletion-induced cell death at
either 4 or 24 h by either LDH or TUNEL assays (Fig. 3a–d).
Combined OGD caused greater injury, increasing LDHdetected cell death 3·9-fold after four-hours. This death continued
at a slower rate on restoration of normal culture conditions
(Fig. 4a,b). Hypothermia to 33°C reduced OGD induced cell
death at four-hours by 37% (P ≤ 0·006; 95% CI 6·8–44·8) (after
correcting for basal injury in controls) (Fig. 4a). Hypothermia
reduced the delayed injury that occurred between removal of
OGD at four-hours and completion of the experiment at 24 h by
80% (P ≤ 0·015; 95% CI 13·8–146·8) (Fig. 4b). The net effect at
24 h was a reduction of LDH release of 42% (P ≤ 0·001; 95% CI
18·3–71·3) (Fig. 4c). TUNEL staining for DNA damage typical of
apoptosis at 24 h suggested that 22% of cell death occurred by this
mechanism and that hypothermia prevented 26% (P ≤ 0·001;
95% CI 12·4–52·2) of this death (after correcting for basal injury
in the control) (Fig. 4d).
To confirm these observations, the H2O2 and OGD experiments
were repeated as before with hypothermia throughout the period
of exposure to injury (from 0 h) and with initiation of hypothermia delayed for one-, three-, or six-hours, with outcome recorded
as the total % of LDH release at 24 h. As before hypothermia had
no impact on cell death in control cultures but when initiated at 0,
one-, three-, or six-hours protected against H2O2 toxicity by 52%
(P ≤ 0·0001; 95% CI 29·8–73·5), 43% (P ≤ 0·0001; 95% CI 20·9–
64·5), 34% (P ≤ 0·001; 95% CI 12·1–55·8), and 21% (P ≤ 0·05;

© 2014 The Authors. International Journal of Stroke published by John Wiley & Sons Ltd
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Fig. 2 The effects of hypothermia on H2O2-induced cell death. Hypothermia reduces LDH detected cell death by 45% at four-hours (a) and effectively
abolished (92% reduction) the delayed injury (b). The net effect at 24 h was reduction of 53% (c). H2O2-induced oxidative stress increased TUNEL-detected
apoptotic cell death 2.9-fold after 24 h and hypothermia prevents 42% of this death (d). Statistical significance detected at *P ≤ 0·05, **P ≤ 0·01,
#P ≤ 0·0005, and ##P ≤ 0·0001. Data presented as mean ± SEM.

Fig. 3 The effects of hypothermia on oxygen deprivation induced cell death. Hypothermia has no beneficial effect at four hours (a), 4–20 h (b), or in the
combined 24 h LDH measurement of cell death (c) as well as on apoptotic cell death detected by TUNEL staining at 24 h (d). NS = not significant.

95% CI 0·57–43·1) (Fig. 5a), respectively, and against OGDinduced injury by 45% (P ≤ 0·0004; 95% CI 18·5–71·9), 30%
(P ≤ 0·023; 95% CI 3·4–56·9), 27% (P ≤ 0·041; 95% CI 0·84–54·3),
and 4% (P = 0·99; 95% CI −23·02 to 30·4) (Fig. 5b), respectively.

Discussion
This study provides the first description of protection of embryonic stem cell-derived human neurons by hypothermia. This is

broadly consistent with data from ∼20 publications (Table 1) that
have examined the effects of hypothermia in tissues cultured from
rats, mice, gerbils, guinea pigs, and three papers utilizing human
teratoma lines (40–50,52,54–56). In this literature, glutamate
release (40), calcium accumulation (38), and glucose utilization
(45) are reduced while membrane potential (41,51) and cellular morphology are restored (49). These are consistent with
reduced injury and cell death (39,44–46,48) measured by
LDH release (40,45), propidium iodide uptake (46,48), 3-(4,5-

© 2014 The Authors. International Journal of Stroke published by John Wiley & Sons Ltd
on behalf of World Stroke Organization

Vol 9, July 2014, 544–552

547

Research

A. Antonic et al.

Fig. 4 The effects of hypothermia on oxygen glucose deprivation (OGD)-induced cell death. Hypothermia reduced OGD-induced cell death at four hours
by 37% (a). Hypothermia reduced the delayed injury that occurred between removal of OGD at four hours and completion of the experiment at 24 h
by 80% (b). The net effect at 24 h was a reduction of LDH release of 42% (c). TUNEL staining for apoptosis at 24 h suggested that 22% of cell death
occurred by this mechanism and that hypothermia prevented 26% of this death (d). *P ≤ 0·05, #P ≤ 0·0005, and ##P ≤ 0·0001. Data presented as
mean ± SEM.

Fig. 5 Time-dependent effects of hypothermia on H2O2 and OGD-induced cell death. Hypothermia reduces LDH-detected cell death induced with H2O2
by 52%, 43%, 34%, and 21% (a) and OGD-induced injury by 45%, 30%, 27%, and 4% when started at 0, one-, three-, and six-hours (b), respectively.
*P ≤ 0·05, **P ≤ 0·01, #P ≤ 0·0005, and ##P ≤ 0·0001. Data presented as mean ± SEM.

dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
staining (54), caspase activity (44), and other immunohistochemical techniques (42,50,52,53,57).
Hypothermia significantly protected embryonic stem cellderived human neurons against oxidative stress and from
hypoxia when glucose concentration was reduced but was ineffective against hypoxia alone. Neuroprotective effects were seen
with delays in initiation of hypothermia of up to six-hours, with
the magnitude of benefit progressively decreasing as the time to
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hypothermia initiation increased. In our preparations protection
against apoptosis was also detected, consistent with data from
mouse neuronal cultures (44) and focal cerebral ischemia
experiments in animals (58) showing that mild hypothermia
attenuates DNA damage typical of apoptotic neuronal cell
death. However, the difference between degree of injury detected
at 24 h by LDH and TUNEL assays suggests cell death is also
occurring in the cultures by nonapoptotic mechanisms such as
necrosis.

© 2014 The Authors. International Journal of Stroke published by John Wiley & Sons Ltd
on behalf of World Stroke Organization

Hypothermia
temperature

35°C, 33°C, and 31°C

32°C

33°C

35°C, 33°C, and 27°C

34°C
31°C

33°C

30°C and 33°C

31°C, 33°C, and 35°C

33°C preconditioning

35°C

27°C or 33°C

35°C and 31°C

34°C pre treatment

34°C, 30°C, or 22°C

33°C preconditioning for
20 min, 1 h before OGD

33°C

33°C and 30°C

Year

1991

1992

1998

1998

2000
2001

2002

2003

2004

2004

2005

2005
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2005

2006

2006

2006

2009

2010

Rat cortical neurons

Human NT2-N neurons

Rat cerebellar cells

Rat hippocampal neurons

Rat hippocampal slices

Rat hippocampal slices

Dissociated mouse hippocampal neurons

Rat hippocampal slices

Rat cerebellar slices

Rat hippocampal slices

Rat retina

Rat cortical cultures

Rat hippocampal slices
Guinea pig hippocampal slices

Rat hippocampal slices

Rat cerebellar granule cells and
GABAergic neurons
Guinea pig E40, E60, and adult slices

Gerbil hippocampal slices

Type of culture

Table 1 Summary of hypothermia use to protect cells in vitro

Hypoxia

OGD

OGD

OGD

OGD

OGD

OGD

OGD

OGD

OGD

OGD

OGD

OGD
OGD

OGD

OGD

OGD

OGD

Injury

24 h

20 min

20 min

Unknown

20 min

40 min

10–25 min

1h

20 min

60 min

1–2 h

Unknown

10–20 min
20, 30, or 40 min

Unknown

2 h and 12 h

3–6 h

Unknown

Duration of injury

Ca2+ accumulation was delayed
following hypothermia treatment
Neuroprotective, reduces LDH caused
cell death
Reduced glutamate release was only
observed in the immature cultures
27°C and 33°C the membrane potential
was restored to the control conditions
Hypothermia reduced CA1 cell loss
When hypothermia added at 0 or 2 h
postinjury induction it reduced energy
metabolic rate
Hypothermia neuronal apoptotic cell
death
Hypothermia reduced glucose utilization
and lactate production
Reduced PI detected cell death only at
31°C and 33°C
Hypothermic preconditioning induces
acute neuroprotection
Protects all regions of hippocampus
from cell death
Decrease in temperature reduced the
spine modality, and the length of
spines was reduced
Decrease in temperature – increased
protection in all the hippocampal
regions
Temperature lowering reduced
OGD-induced cell death
Expression of Bcl-2 was increased with
decrease in temperature
Hypothermic preconditioning increased
survival of Purkinje neurons in rat
cerebellar slices after OGD
Posthypoxic hypothermia is protective in
human NT2-N neurons
Increased cell survival following
hypothermia

Intracellular Ca2+ accumulation

Cell viability

MTT

Expression of Bcl-2, fluorescence
magnitude of intracellular Ca2+
Immunohistochemistry

Electrophysiology

Immunohistochemistry

Spine shape and motility assessed by
microscopy

Propidium iodide

Immunohistochemistry

Propidium iodide (PI)

LDH

Caspase 3–8 and −9 activity

Extracellular membrane potential
recordings
Immunohistochemistry
Recovery of energy metabolism

HPLC

LDH

Outcome

Outcome measure

(55)

(54)

(53)

(52)

(51)

(50)

(49)

(48)

(47)

(46)

(45)

(44)

(42)
(43)

(41)

(40)

(39)

(38)

Reference
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There are a number of studies using NT2-N neurons in similar
experiments with conflicting data evident. Although one study
reports essentially the same result as here (54), another reports
that hypothermia protects against the effects of oxygen restriction
alone (59). The reasons for these differences are unclear but
suggest differential expression of the metabolic or signaling
machinery involved in ischemic injury. NT2-N cells are derived
from the human NTera2 embryonal carcinoma stem cell line (60)
and are known to differ substantially in their broad pattern of
gene expression when compared with different hESC lines (61)
and therefore may not be the most appropriate models to study
human disease (62).
Intriguingly, hypothermia had no effect on the basal level of cell
death in the uninjured controls. The contrasting response to different injury models, lack of effect on culture dependent cell
death, and different behaviors to experiments reported in other
cell lines suggests interaction specifically in the processes of ischemic injury rather than cell death itself and requires further study.
These differences also do not appear to be consistent with
hypothermia-inducing protection simply by slowing overall
metabolic activity (63) but could still be consistent with decreasing the cerebral metabolic rates of glucose and oxygen consumption (64) and slowing adenosine triphosphate (ATP) breakdown
(65).
It is not clear how the time frame of protection of human
neurons in vitro will be predictive of time frame in stroke.
However, detection of protection against oxidative stress even
after cessation of injury offers hope for the clinical setting. This
may be particularly relevant if reperfusion injury (66–68) acts to
lessen the potential benefit afforded by thrombolysis or thrombectomy and suggests this may be an important target for clinical
trials of hypothermia. The data are certainly consistent with the
recent observation that mild hypothermia reduces the deleterious
side effects of tissue plasminogen activator treatment after thromboembolic stroke in rats (69). Different time frames of benefit via
different mechanisms for a single therapeutic approach suggest
we still have much to learn about the details of the ischemic
cascade and the therapeutic opportunities it might offer. The
window of opportunity detected here in human neurons in vitro
is certainly consistent with a wide window in rodent models of
stroke (20) and with the planned six-hour window for
EuroHYP-1 (70).
As in most experiments, our data and its interpretation have
limits. The current experiments have been performed in cells that
exhibit a branching phenotype expressing β III tubulin. However,
these cells have spent only 11 days in culture and thus might be
better viewed as immature. It is not yet clear whether these cells
can stand in for a 60-year-old neuron from a typical stroke victim.
However, it seems reasonable to believe that we can devise strategies to rapidly and repeatedly stress them much as a car manufacture would stress test a car. Nevertheless, we might see different
effects when cultures have matured neurochemically. Moreover,
clinically relevant protection might be dependent on effects on
neurotransmission itself (71) or regulation of edema (72). Furthermore, beneficial effects might be restricted to specific neurochemical profiles present at high abundance in our culture but
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not in areas of the brain affected by most common forms of
human stroke. Another limitation of the current experiments was
ethical approval to study only one hESC cell line. It will be important to confirm these observations in other hESC lines, and when
the technology is more mature (73,74) to examine whether the
same effects are seen in induced pluripotent stem cells (iPSCs)
from patients with stroke or relevant defects of oxidative metabolism such as seen in inborn errors of mitochondrial function.

Conclusion
This study provides the first description of protection of embryonic stem cell derived human neurons by hypothermia. If hypothermia does have a predilection for ischemic processes, this
offers hope for use of hypothermia to treat ischemic stroke and
spinal cord injuries where cord compression results in secondary
ischemia (75). This study also provides proof of principle that
human neurons derived from hESCs can be used to screen new
drugs for therapeutic effect. For screening large chemical libraries,
this will be more specific than screening in cell lines from other
species, and more cost-effective than initial screening in animal
models of stroke.
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